RxDoctor Payments Data

Andrew Kowalski, MD

Nephrology · Addison, ILNPI 1114293123

Payments from drug & device makers

$2,481in general payments, 2019–2025

Across 79 payments — averaging $31.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$409
  • AstraZeneca$385
  • Medtronic$192
  • Otsuka America Pharmaceutical, Inc.$167
  • Johnson & Johnson$149
  • Vifor Pharma, Inc.$129
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$2,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,481 in reported general payments places this provider in the 70th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$89,349
Medicare patients
214
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$88,455
FarxigaDapagliflozin Propanediol87$57,009
LokelmaSodium Zirconium Cyclosilicate27$23,420
VeltassaPatiromer Calcium Sorbitex17$18,732
JanuviaSitagliptin Phosphate11$11,268
Sevelamer Carbonate27$2,874
Torsemide52$1,657
Chlorthalidone25$649
Calcitriol28$630
Valsartan12$438
Tamsulosin Hcl16$426
Lisinopril23$237
Carvedilol33$176
Nifedipine ErNifedipine13$165
Lidocaine-PrilocaineLidocaine/Prilocaine12$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$119$88,455103 claims
AstraZenecaFarxiga, Lokelma$385$80,428114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 524 nephrology providers in Illinois.

Other nephrology in Addison

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →